Revolution Medicines Inc-28 (RVMDW) SEC 13F Holdings (Q2 2026): Institutional Buyers & Sellers

RVMDW ranks #8080 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

RVMDW is a disclosed holding of David Shaw (D. E. Shaw & Co.), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

23 institutions disclose a position in RVMDW, but none treat it as a major bet — even Rangeley Capital, LLC, its most concentrated holder, allocates just 4.3% of its own portfolio to it.

LMR Partners LLP has added to its RVMDW position for two straight quarters, increasing it by $44.6M to reach $47.5M today.

RVMDW reported a net loss of $1.8B over the trailing twelve months.

• Not yet profitable — net loss of $1.8B over the trailing twelve months
• Revenue declined 100.0% year over year
• Net income declined year over year, from -$812.1M to -$1.8B
• Operating cash flow was negative, using $897.7M in cash
• Current ratio of 7.14x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.44x equity — within a conventional range